BioLife Solutions Inc (NASDAQ:BLFS) VP James Mathers sold 2,500 shares of BioLife Solutions stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $17.15, for a total value of $42,875.00. Following the transaction, the vice president now owns 19,884 shares in the company, valued at approximately $341,010.60. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
James Mathers also recently made the following trade(s):
- On Tuesday, July 9th, James Mathers sold 2,500 shares of BioLife Solutions stock. The shares were sold at an average price of $17.94, for a total value of $44,850.00.
NASDAQ BLFS traded down $0.03 during trading on Thursday, hitting $17.24. The stock had a trading volume of 138,656 shares, compared to its average volume of 173,845. The firm has a market cap of $324.10 million, a P/E ratio of 123.14 and a beta of 1.32. The company has a 50-day moving average price of $17.24. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.50 and a quick ratio of 12.99. BioLife Solutions Inc has a 12 month low of $9.15 and a 12 month high of $26.35.
Several equities analysts have recently weighed in on the company. Maxim Group set a $24.00 price objective on BioLife Solutions and gave the company a “buy” rating in a report on Wednesday, May 22nd. Northland Securities lifted their price objective on Paycom Software from $215.00 to $275.00 and gave the company an “outperform” rating in a report on Tuesday. Zacks Investment Research cut ExlService from a “hold” rating to a “sell” rating in a report on Wednesday. ValuEngine upgraded XCel Brands from a “sell” rating to a “hold” rating in a report on Tuesday. Finally, BidaskClub upgraded Xilinx from a “hold” rating to a “buy” rating in a report on Saturday, June 29th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $17.80.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BLFS. FMR LLC bought a new stake in BioLife Solutions in the 1st quarter valued at approximately $2,684,000. Ranger Investment Management L.P. bought a new stake in BioLife Solutions in the 4th quarter valued at approximately $1,108,000. Barclays PLC lifted its stake in BioLife Solutions by 18,125.0% in the 4th quarter. Barclays PLC now owns 72,900 shares of the medical equipment provider’s stock valued at $877,000 after acquiring an additional 72,500 shares in the last quarter. Quantum Capital Management bought a new stake in BioLife Solutions in the 1st quarter valued at approximately $852,000. Finally, Roubaix Capital LLC bought a new stake in BioLife Solutions in the 1st quarter valued at approximately $809,000. Hedge funds and other institutional investors own 45.76% of the company’s stock.
BioLife Solutions Company Profile
BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.
See Also: What is the Quick Ratio?
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.